177 related articles for article (PubMed ID: 30592246)
1. Relationship between cyclosporine area-under-the curve and acute graft versus host disease in pediatric patients undergoing hematopoietic stem cell transplant: A prospective, multicenter study.
Schechter T; Lewis VA; Schultz KR; Mitchell D; Chen S; Seto W; Teuffel O; Gibson P; Doyle JJ; Gassas A; Sung L; Lee Dupuis L
Pediatr Hematol Oncol; 2018 May; 35(4):288-296. PubMed ID: 30592246
[TBL] [Abstract][Full Text] [Related]
2. Achievement of target cyclosporine concentrations as a predictor of severe acute graft versus host disease in children undergoing hematopoietic stem cell transplantation and receiving cyclosporine and methotrexate prophylaxis.
Punnett A; Sung L; Price V; Das P; Diezi M; Doyle J; Dupuis LL
Ther Drug Monit; 2007 Dec; 29(6):750-7. PubMed ID: 18043472
[TBL] [Abstract][Full Text] [Related]
3. Prediction of area under the cyclosporine concentration versus time curve in children undergoing hematopoietic stem cell transplantation.
Dupuis LL; Seto W; Teuffel O; Gibson P; Schultz KR; Doyle JD; Gassas A; Egeler RM; Sung L; Schechter T
Biol Blood Marrow Transplant; 2013 Mar; 19(3):418-23. PubMed ID: 23128321
[TBL] [Abstract][Full Text] [Related]
4. Determination of area under the whole blood concentration versus time curve after first intravenous cyclosporine dose in children undergoing hematopoietic stem cell transplant: limited sampling strategies.
Sibbald C; Seto W; Taylor T; Saunders EF; Doyle J; Dupuis LL
Ther Drug Monit; 2008 Aug; 30(4):434-8. PubMed ID: 18641547
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor-alpha gene polymorphisms are associated with severity of acute graft-versus-host disease following matched unrelated donor bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium study.
Goyal RK; Lin Y; Schultz KR; Ferrell RE; Kim Y; Fairfull L; Livote E; Yanik G; Atlas M
Biol Blood Marrow Transplant; 2010 Jul; 16(7):927-936.e1. PubMed ID: 20100586
[TBL] [Abstract][Full Text] [Related]
6. A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients.
Windreich RM; Goyal RK; Joshi R; Kenkre TS; Howrie D; Venkataramanan R
Biol Blood Marrow Transplant; 2016 Apr; 22(4):682-689. PubMed ID: 26740371
[TBL] [Abstract][Full Text] [Related]
7. Intestinal Microbiota Can Predict Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation.
Han L; Zhang H; Chen S; Zhou L; Li Y; Zhao K; Huang F; Fan Z; Xuan L; Zhang X; Dai M; Lin Q; Jiang Z; Peng J; Jin H; Liu Q
Biol Blood Marrow Transplant; 2019 Oct; 25(10):1944-1955. PubMed ID: 31299215
[TBL] [Abstract][Full Text] [Related]
8. Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors.
Lazaryan A; Weisdorf DJ; DeFor T; Brunstein CG; MacMillan ML; Bejanyan N; Holtan S; Blazar BR; Wagner JE; Arora M
Biol Blood Marrow Transplant; 2016 Jan; 22(1):134-40. PubMed ID: 26365153
[TBL] [Abstract][Full Text] [Related]
9. A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses.
Khandelwal P; Fukuda T; Mizuno K; Teusink-Cross A; Mehta PA; Marsh RA; Kashuba ADM; Vinks AA; Davies SM
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1829-1835. PubMed ID: 27498124
[TBL] [Abstract][Full Text] [Related]
10. Peritransplant Serum Albumin Decline Predicts Subsequent Severe Acute Graft-versus-Host Disease after Mucotoxic Myeloablative Conditioning.
Rashidi A; DiPersio JF; Westervelt P; Abboud CN; Schroeder MA; Cashen AF; Pusic I; Romee R
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1137-1141. PubMed ID: 26988741
[TBL] [Abstract][Full Text] [Related]
11. Diarrhea during the conditioning regimen is correlated with the occurrence of severe acute graft-versus-host disease through systemic release of inflammatory cytokines.
Liu D; Yan C; Xu L; Wang Y; Han W; Zhang X; Liu K; Huang X
Biol Blood Marrow Transplant; 2010 Nov; 16(11):1567-75. PubMed ID: 20546909
[TBL] [Abstract][Full Text] [Related]
12. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
[TBL] [Abstract][Full Text] [Related]
13. Toward optimization of cyclosporine concentration target to prevent acute graft-versus-host disease following myeloablative allogeneic stem cell transplant.
Kwan ACF; Blosser N; Ghosh S; Leyshon C; Dersch-Mills D; Puckrin R; Duggan P; Zepeda V; Savoie L; Stewart D; Storek J; Jamani K
Clin Transplant; 2022 Aug; 36(8):e14732. PubMed ID: 35606904
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
Ayuk F; Diyachenko G; Zabelina T; Wolschke C; Fehse B; Bacher U; Erttmann R; Kröger N; Zander AR
Biol Blood Marrow Transplant; 2008 Aug; 14(8):913-9. PubMed ID: 18640575
[TBL] [Abstract][Full Text] [Related]
15. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation.
Törlén J; Ringdén O; Garming-Legert K; Ljungman P; Winiarski J; Remes K; Itälä-Remes M; Remberger M; Mattsson J
Haematologica; 2016 Nov; 101(11):1417-1425. PubMed ID: 27662016
[TBL] [Abstract][Full Text] [Related]
16. Effect of acute graft-versus-host disease on the outcome of second allogeneic hematopoietic stem cell transplant in children.
Schechter T; Avila L; Frangoul H; Domm J; Dupuis LL; Naithani R; Zhao X; Pollock-Barziv S; Roifman C; Gassas A; Doyle J
Leuk Lymphoma; 2013 Jan; 54(1):105-9. PubMed ID: 22721498
[TBL] [Abstract][Full Text] [Related]
17. [Mycophenolate mofetil in treatment of graft-versus-host disease after allogeneic hematopoietic cell transplantation: analysis of 44 cases].
Chen H; Liu KY; Liu DH; Xu LP; Han W; Chen YH; Huang XJ
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2127-30. PubMed ID: 19080474
[TBL] [Abstract][Full Text] [Related]
18. Early (day -7) versus conventional (day -1) inception of cyclosporine-A for graft-versus-host disease prophylaxis after unrelated donor hematopoietic stem cell transplantation in children. Long-term results of an AIEOP prospective, randomized study.
Lanino E; Rondelli R; Locatelli F; Messina C; Pession A; Balduzzi A; Favre C; Santarone S; Rabusin M; Pollichieni S; Cesaro S; Dini G;
Biol Blood Marrow Transplant; 2009 Jun; 15(6):741-8. PubMed ID: 19450759
[TBL] [Abstract][Full Text] [Related]
19. [Clinical study on haploid HLA-matched hematopoietic stem cell transplantation for treatment of malignant hematological disease].
Sun AN; Wu DP; Wang Y; Qiu HY; Jin ZM; Miao M; Tang XW; Fu ZZ; Ma X; Han Y; He GS; Chen SN; Xue SL; Zhao Y
Ai Zheng; 2006 Aug; 25(8):1019-22. PubMed ID: 16965686
[TBL] [Abstract][Full Text] [Related]
20. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
